Today, the Nexium district court will hear arguments on
the Ranbaxy defendants' motion for a mistrial. As we have
previously reported (click here, here and here to read more), In re:
Nexium is the first pay-for-delay case to go to trial
since the Supreme Court's Federal Trade Commission v.
Actavis decision.
At the heart of Ranbaxy's motion is their claim that they
will suffer incurable prejudice because the Court has changed its
position on which reverse payment may form the basis for
plaintiffs' case. According to Ranbaxy, in every single ruling that the court
has issued after and including its summary judgment decision, the
court has held that the only alleged reverse payment at issue is
the AstraZeneca-Teva settlement—not the AstraZeneca-Ranbaxy
settlement. Based upon these repeated rulings, the Ranbaxy
defendants structured their trial defense to defend against claims
premised solely on the AstraZeneca-Teva settlement.